MetaCap

Actuate Therapeutics (ACTU) vs MIRA Pharmaceuticals (MIRA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

MIRA Pharmaceuticals (MIRA) has outperformed Actuate Therapeutics (ACTU) over the past year, losing 79.1% versus a loss of 96.4%. Actuate Therapeutics is the larger company by market cap ($13.6 million vs $12.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACTU-96.43%MIRA-79.06%
+27%-38%-102%
Nov 21, 20251 yearNov 20, 2026
ACTU-97.41%MIRA-84.92%
+43%-30%-104%
Aug 12, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACTU versus MIRA key metrics
MetricACTUMIRA
Share price$0.2253$0.291
Market cap$13.60M$12.23M
1-day change+5.38%-20.84%
YTD return-96.32%-80.73%
1-year return-96.43%-79.06%
P/E ratio (TTM)—29.10
EPS (TTM)$-0.76$0.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-22.23M$-10.44M
52-week high$7.90$1.69
52-week low$0.174$0.255
Distance from 52-week high-97.15%-82.78%
Analyst consensusnonenone
Avg. price target upside+5084.20%+1102.75%
Average volume807.24K622.02K
Shares outstanding60.38M42.02M
Employees12—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MIRA has outperformed ACTU by 17.4 percentage points over the past year.

About Actuate Therapeutics

ACTU stock →

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

About MIRA Pharmaceuticals

MIRA stock →

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders.

Health Care · Biotechnology: Pharmaceutical Preparations

ACTU vs MIRA FAQ

Which is bigger, Actuate Therapeutics or MIRA Pharmaceuticals?

Actuate Therapeutics (ACTU) is larger, with a market capitalization of $13.60M compared with $12.23M for MIRA Pharmaceuticals (MIRA).

Which stock has performed better over the past year, ACTU or MIRA?

MIRA returned -79.06% over the past 12 months, compared with -96.43% for ACTU (price return, excluding dividends). Past performance does not predict future results.

Are Actuate Therapeutics and MIRA Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons